Melanoma Protocol - ADVANCED - S1320

S1320

A Randomized Phase II Trial of Intermittent vs Continuous Dosing of Dafrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF v600/k Mutant Melanoma.